Simplex Trading
CRNX

Simplex Trading’s Crinetics Pharmaceuticals CRNX Stock Holding History

Simplex Trading’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-108
Closed -$4.01K – 9425
2026
Q1 		$3.92K Buy
+108
New +$4.82K ﹤0.01% 8040
2025
Q4 		– Sell
-1,944
Closed -$80K – 8787
2025
Q3 		$80K Sell
1,944
-3,397
-64% -$109K ﹤0.01% 5995
2025
Q2 		$153K Buy
5,341
+5,167
+2,970% +$160K ﹤0.01% 4786
2025
Q1 		$5K Sell
174
-86
-33% -$3.21K ﹤0.01% 7526
2024
Q4 		$13K Buy
+260
New +$14.5K ﹤0.01% 6995
2024
Q1 		– Sell
-23,534
Closed -$921K – 8981
2023
Q4 		$837K Sell
23,534
-86,842
-79% -$2.66M ﹤0.01% 3177
2023
Q3 		$3.28M Buy
110,376
+107,831
+4,237% +$2.22M ﹤0.01% 1643
2023
Q2 		$45K Buy
+2,545
New +$50.7K ﹤0.01% 5937
2022
Q3 		– Sell
-552
Closed -$11.3K – 10029
2022
Q2 		$10K Sell
552
-37,602
-99% -$750K ﹤0.01% 8271
2022
Q1 		$837K Buy
38,154
+17,874
+88% +$362K ﹤0.01% 3126
2021
Q4 		$576K Buy
+20,280
New +$500K ﹤0.01% 3608

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Simplex Trading's CRNX Position: Q2 2026 in Review

Simplex Trading sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2026, closing a stake of 108 shares — an estimated $4.01K sold.

Simplex Trading first reported a position in CRNX in Q4 2021 and held it in 11 quarters. The position peaked at $3.28M in Q3 2023. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Simplex Trading reported no remaining Crinetics Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 108 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $4.01K.
  • Simplex Trading first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • Simplex Trading's Crinetics Pharmaceuticals position peaked at $3.28M in Q3 2023.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.